EP Patent

EP2540350A1 — Combinations of a macrocyclic quinoxaline compound which is an HCV NS3 protease inhibitors with other HCV agents

Assigned to MSD Italia SRL · Expires 2013-01-02 · 13y expired

What this patent protects

The present invention relates to a macrocyclic compound of formula (I) useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in combination with other therapeutic agents.

USPTO Abstract

The present invention relates to a macrocyclic compound of formula (I) useful as inhibitors of the hepatitis C virus (HCV) NS3 protease, and in treating or preventing HCV infections, in combination with other therapeutic agents.

Drugs covered by this patent

Patent Metadata

Patent number
EP2540350A1
Jurisdiction
EP
Classification
—
Expires
2013-01-02
Drug substance claim
No
Drug product claim
No
Assignee
MSD Italia SRL
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.